Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today ...

Advanced environmental performance through renewable energy transition and enhanced carbon transparencyStrengthened sustainability management and supply chain engagement across the healthcare value ...

This final phase is an opportunity to join MBA programs designed to combine rigorous academics with hands-on industry ...

METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an ...

LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...

Seven internationally recognized nephrology experts join R1's Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the ...

PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc.

A controversial Honolulu City Council measure connected to a proposed Haleiwa housing and commercial development has returned for further consideration after being put on hold almost a year ago amid ...

A pair of rehabilitation projects are set to add housing and businesses to the downtown areas in two Michigan cities.

A controversial City Council measure connected to a proposed Haleiwa housing and commercial development has returned for further consideration after being put on hold almost a year ago amid ...

The Centers for Medicare and Medicaid Services (CMS) is launching a pilot program on July 1 to subsidize costs of GLP-1s ...